$16.16−0.46 (−2.77%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Aktis Oncology (AKTS) Key Ratios
Valuation, quality, health and growth. Every ratio ranked against its sector peers — the number we score — with its own ten-year record shown beside it for context.
Sources Company filings and market prices Filings and pricesRatios computed How we compute thisNot investment advice
VALUE
No data
no inputs scored
QUALITY
Weak
below-peer returns
HEALTH
Sturdy
leverage data unavailable; scored on the rest
GROWTH
Not scored
no measurable growth rate; left out of the composite
In one line
A weak business at a no data price: quality 29, health 74, each a percentile within Healthcare.
Every figure here is from the latest fiscal year. The note under each row says why.track = where peers land, worse → better (direction-adjusted: right always means better)▏sector median● you are here▲ where today's value sits in the company's own 10-year record (context, not scored)hover any metric for its formula
Valuation
no inputs scoredEBIT (operating income) for the latest fiscal year ÷ enterprise value on the current market cap (Greenblatt). The vendor's own earnings yield is net income to common ÷ market cap, a different figure.—Not meaningful: operating income is zero or negative.
Financial health
74th pctileleverage data unavailable; scored on the rest7.3773rd pctileown record too shortFiscal 2025 (Dec 31, 2025)Fiscal 2025: a quarter is missing from the last four
(Cash, short-term investments and receivables) ÷ current liabilities, as the data vendor builds it. Its receivables include non-trade receivables, which Tenet's balance sheet shows inside other current assets.7.3775th pctileown record too shortFiscal 2025 (Dec 31, 2025)Fiscal 2025: a quarter is missing from the last four
(Total debt − cash) ÷ EBITDA—Not meaningful: EBITDA is zero or negative.
Profitability & returns
29th pctilebelow-peer returnsGrowth
no measurable growth rate; left out of the compositeThe yearly rate that compounds the earliest fiscal year's revenue into the latest one, over the true number of fiscal years between them (up to five). When the earliest year's revenue is zero or negative, the rate starts from the first later year with at least $10M of revenue, provided at least three years remain.—This growth figure starts in a period outside the history your plan includes.
★ Corrected metrics: why we compute these ourselves
the receipts behind the numbers aboveGreenblatt earnings yield—EBIT ÷ EV The vendor's "earningsYield" is NI ÷ market cap, which is not Greenblatt's formula.
ROIC−32%NOPAT ÷ invested capital The vendor's simple ROIC, not its tiny-base roic tag; withheld when a negative EBIT flips its sign.
Interest coverage— Guarded, not faked: we have no interest-expense figure on file for this company, so it's excluded from the ranking instead of rendered as garbage.
Every raw line behind these ratios→
All three statements: 5 years free, 10 on Premium, 20 on Ultimate
Quarterly, in fiscal years: 1 free, 5 on Premium, Unlimited on Ultimate
These percentiles feed the value, income, timing and long-hold tenets→
See which criteria pass, with the number as of the last close and the rule behind each
Percentiles computed nightly against 409 Healthcare peers from our ingested fundamentals DB · raw statements for corrected metrics. Direction-adjusted: for "lower is better" ratios (P/E, D/E…) the percentile is flipped so right always means better. The percentile is the stock's rank among sector peers, the number that is scored. The triangle marks where the current value sits in the company's own ten-year annual record, shown for context and never blended into the score. Computed Nov 16, 2026 · Not investment advice.

